Literature DB >> 24568512

Survival of patients with prostate cancer in Yazd, Iran.

Shokouh Taghipour Zahir1, Mohammad Reza Nazemian, Sanaz Zand, Samad Zare.   

Abstract

BACKGROUND: Prostate cancer is the second leading cause of cancer death in men worldwide. Several factors such as availability of screening tests, and dietary, other lifestyle, environmental and genetic influences contribute to worldwide disparities in prostate cancer incidence and mortality rates. Our aims were to investigate patient characteristics at the time of diagnosis, common treatment strategies employed and survival in an Iranian male population with prostate cancer.
MATERIALS AND METHODS: Archives of Pathology Departments of five referral centers affiliated with the School of Medicine of Shahid Sadoughi University in Yazd province were reviewed. Paraffin-embedded blocks were reviewed by two independent pathologists to confirm the diagnosis. The latest modification of the Gleason Scoring System was adopted to determine pathological grading. Following pathological evaluation, patients were contacted via telephone to acquire information regarding their current status.
RESULTS: Pathology blocks were available for 113 patients. However, upon phone contacts, we were unable to determine the survival status in 23 patients (response rate=83%). Therefore, 90 patients were enrolled in the final analysis. The median follow-up time was 6.0 years (ranging from 0.3 to 8.8 years). There were 30 death attributed to prostate cancer in the study group. Kaplan-Meier analysis revealed that patient age at the time of diagnosis was a significant predictor of survival. Another significant predictor of poorer survival was higher tumor grade.
CONCLUSIONS: Our observations indicate that age and pathological grade can negatively affect survival of individuals with prostate cancer in Iran.

Entities:  

Mesh:

Year:  2014        PMID: 24568512     DOI: 10.7314/apjcp.2014.15.2.883

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Yield of prostate cancer screening at a community based clinic in Saudi Arabia.

Authors:  Abdulaziz A Almutairi; Abdelmoneim M Edali; Shoaib A Khan; Wala A Aldihan; Abdullah H Alkhenizan
Journal:  Saudi Med J       Date:  2019-07       Impact factor: 1.484

2.  Survival Rate of Prostate Cancer in Asian Countries: A Systematic Review and Meta-Analysis.

Authors:  Soheil Hassanipour; Hamed Delam; Morteza Arab-Zozani; Elham Abdzadeh; Seyyed Ali Hosseini; Hossein-Ali Nikbakht; Mahdi Malakoutikhah; Mohammad Taghi Ashoobi; Mohammad Fathalipour; Hamid Salehiniya; Shirin Riahi
Journal:  Ann Glob Health       Date:  2020-01-02       Impact factor: 2.462

3.  Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study.

Authors:  Mojtaba Mirzaei; Mahboobehsadat Mirzadeh; Mohsen Mirzaei
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

4.  IcarisideII facilitates the differentiation of ADSCs to SCs via let-7i/STAT3 axis to preserve erectile function.

Authors:  Pingyu Ge; Yinxue Guo; Jun Shen
Journal:  Biol Res       Date:  2019-10-03       Impact factor: 5.612

5.  Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018).

Authors:  Mohammad Aziz Rasouli; Ghobad Moradi; Bushra Zareie; Heshmatollah Sofimajidpour; Sima Tozandehjani; Hedyeh Zafari; Fatemeh Gholami; Sonia Shahsavari; Parisa Hassani; Mahshid Mohammadian
Journal:  BMC Cancer       Date:  2021-12-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.